Studies have shown that five cytochrome P450 1B1 (CYP1B1) variants, which could change the hydroxylation activity of estrogen, have greater than twofold higher activity than the wild-type enzyme, thereby increasing the risk for cancers (57). Here, CYP1B1 is linked to cancer.